{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:10:43Z","timestamp":1762866643146},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"DOI":"10.2146\/ajhp140449","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T12:14:06Z","timestamp":1437394446000},"page":"1271-1278","source":"Crossref","is-referenced-by-count":11,"title":["Vedolizumab: An integrin-receptor antagonist for treatment of Crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1093","volume":"72","author":[{"given":"Lindsay","family":"Hahn","sequence":"first","affiliation":[{"name":"College of Pharmacy, Belmont University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashton","family":"Beggs","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Belmont University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy","family":"Wahaib","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Belmont University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leela","family":"Kodali","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Belmont University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Belmont University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041604585587200_b1-0721271","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ibd.21048","article-title":"World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010","volume":"16","author":"Bernstein","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"suppl 1","key":"2019041604585587200_b2-0721271","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2011.58","article-title":"An evidence-based systematic review on medical therapies for inflammatory bowel disease","volume":"106","author":"Talley","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019041604585587200_b3-0721271","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2019041604585587200_b4-0721271","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2019041604585587200_b5-0721271","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","article-title":"Recent trends in the prevalence of Crohn\u2019s disease and ulcerative colitis in a commercially insured US population","volume":"58","author":"Kappelman","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2019041604585587200_b6-0721271","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"2019041604585587200_b7-0721271","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med"},{"key":"2019041604585587200_b8-0721271","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/imt.12.85","article-title":"Vedolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease","volume":"4","author":"McLean","year":"2012","journal-title":"Immunotherapy"},{"key":"2019041604585587200_b9-0721271","unstructured":"Food and Drug Administration. FDA approves Entyvio to treat ulcerative colitis and Crohn\u2019s disease. www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm398065.htm (accessed 2014 May 23)."},{"key":"2019041604585587200_b10-0721271","first-page":"123","article-title":"New and emerging treatments for ulcerative colitis: a focus on vedolizumab","volume":"7","author":"Gledhill","year":"2013","journal-title":"Biologics"},{"key":"2019041604585587200_b11-0721271","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11894-012-0311-3","article-title":"Novel targets for inflammatory bowel disease therapeutics","volume":"15","author":"Lowenberg","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"2019041604585587200_b12-0721271","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-013-0176-2","article-title":"T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects","volume":"74","author":"Mosli","year":"2014","journal-title":"Drugs"},{"key":"2019041604585587200_b13-0721271","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1756283X09356872","article-title":"Current directions of biologic therapies in inflammatory bowel disease","volume":"3","author":"Reenaers","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"2019041604585587200_b14-0721271","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/gut.45.6.856","article-title":"Expression of lymphocyte-endothelial receptor-ligand pairs, \u03b14\u03b27\/MAdCAM-1 and OX40\/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease","volume":"45","author":"Souza","year":"1999","journal-title":"Gut"},{"key":"2019041604585587200_b15-0721271","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/08830185.2012.690794","article-title":"Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease","volume":"31","author":"Ghosh","year":"2012","journal-title":"Int Rev Immunol"},{"key":"2019041604585587200_b16-0721271","unstructured":"Food and Drug Administration. FDA drug safety communication: risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab). www.fda.gov\/Drugs\/DrugSafety\/ucm252045.htm (accessed 2014 May 23)."},{"key":"2019041604585587200_b17-0721271","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/1751-2980.12048","article-title":"Recent developments in the treatment of inflammatory bowel disease","volume":"14","author":"Rietdijk","year":"2013","journal-title":"J Dig Dis"},{"key":"2019041604585587200_b18-0721271","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3748\/wjg.v20.i5.1139","article-title":"When combination therapy isn\u2019t working: emerging therapies for the management of inflammatory bowel disease","volume":"20","author":"Krishnareddy","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2019041604585587200_b19-0721271","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2019041604585587200_b20-0721271","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2019041604585587200_b21-0721271","volume-title":"Entyvio (vedolizumab) package insert","year":"2014"},{"issue":"suppl 1","key":"2019041604585587200_b22-0721271","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S1873-9946(14)60505-5","article-title":"Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn\u2019s disease","volume":"8","author":"Rosario","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019041604585587200_b23-0721271","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.3748\/wjg.14.4127","article-title":"Use of Crohn\u2019s disease activity index in clinical trials of biologic agents","volume":"14","author":"Freeman","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2019041604585587200_b24-0721271","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"2019041604585587200_b25-0721271","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist therapy failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"2019041604585587200_b26-0721271","first-page":"4","article-title":"What is the role of vedolizumab in the era of anti-TNF agents?","volume":"2","author":"Cheng","year":"2014","journal-title":"Ann Transl Med"},{"key":"2019041604585587200_b27-0721271","volume-title":"Remicade (infliximab) package insert","year":"2013"},{"key":"2019041604585587200_b28-0721271","volume-title":"Red Book Online [online database]"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/15\/1271\/28451339\/ajhp1271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T05:00:02Z","timestamp":1555390802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/15\/1271\/5111725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140449","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,8,1]]},"published":{"date-parts":[[2015,8,1]]}}}